Company profile: Spero Therapeutics
1.1 - Company Overview
Company description
- Provider of oral and IV antibiotic therapies for gram-negative infections: Tebipenem HBr for complicated urinary tract infections and acute pyelonephritis to reduce hospitalizations and support transition from IV to home care; SPR720, an oral investigational agent for nontuberculous mycobacterial pulmonary disease; and SPR206, an IV candidate for multidrug-resistant Gram-negative infections.
Products and services
- SPR206: Intravenous antibiotic candidate treating multi-drug resistant Gram-negative infections in hospital settings, enabling IV dosing suited to inpatient care
- Tebipenem HBr: Oral antibiotic treating complicated urinary tract infections and acute pyelonephritis, aiming to reduce hospitalizations and enable transition from IV therapy to home care through oral administration
- SPR720: Oral investigational antibacterial agent for nontuberculous mycobacterial pulmonary disease, targeting enzymes essential for bacterial DNA replication to treat NTM infections with enzyme-directed antibacterial activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spero Therapeutics
IQuum
HQ: United States
Website
- Description: Provider of molecular diagnostics and biological sample technology, developing an early-stage platform to improve extraction of information from biological samples and deliver recent advances in genomics and biotechnology to healthcare and daily life; founded in 1998 in the Boston metropolitan area.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IQuum company profile →
Cellestis
HQ: Australia
Website
- Description: Provider of QuantiFERON products for medical diagnosis and scientific research, utilizing a patented whole blood method to detect cell-mediated immune responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellestis company profile →
Tetraphase Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics for significant disease categories, including GIAPREZA to increase blood pressure in adults with septic or other distributive shock; XERAVA for complicated intra-abdominal infections in adults; XACDURO for hospital- and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex; and investigational zoliflodacin for uncomplicated gonorrhea.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetraphase Pharmaceuticals company profile →
Okogen
HQ: United States
Website
- Description: Provider of ophthalmic anti-infective drug candidates, including OKG-0303, a fixed-dose combination eyedrop for acute infectious conjunctivitis that combines an antiviral, ocular decongestant, and antibacterial; OKG-0301, an antiviral shown to inhibit viral replication in adenoviral conjunctivitis; and the RUBY trial evaluating the safety and efficacy of OKG-0301.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Okogen company profile →
Mesa Biotech
HQ: United States
Website
- Description: Provider of DNA and RNA molecular testing services and COVID-19 diagnostic products, including the Accula SARS-CoV-2 molecular test and testing kits with high-throughput and rapid tests, controls, combo kits, reagents, and buffers. Based in San Diego, California, with a satellite testing laboratory in Santa Fe, New Mexico.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mesa Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spero Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spero Therapeutics
2.2 - Growth funds investing in similar companies to Spero Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spero Therapeutics
4.2 - Public trading comparable groups for Spero Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →